犬尿氨酸3-单加氧酶抑制剂GSK180减轻大鼠创伤后脓毒症诱导急性肾损伤的机制
该研究为动物实验,采用雄性SPF级SD大鼠建立创伤后脓毒症诱导急性肾损伤模型,先通过蛋白质组学筛选出KMO为候选靶点,再以KMO抑制剂GSK180(10 mg/kg)于造模后2小时腹腔注射干预。结果显示,与TIS组相比,GSK180干预组WBC、TNF-α、IL-6、CRP、SCr、BUN均降低(均P<0.05),肾脏病理损伤、细胞凋亡及线粒体超微结构损伤减轻,线粒体ROS降低、膜电位稳定,p-DRP1 Ser616和BAX表达下降,MFN2和OPA1表达上调(均P<0.05)。作者结论认为KMO在TIS诱导的AKI中上调并介导肾损伤,GSK180通过抑制DRP1介导的线粒体分裂、促进MFN2/OPA1依赖的线粒体融合发挥肾脏保护作用。
要点
- 在大鼠创伤后脓毒症诱导AKI模型中,造模后2小时腹腔注射GSK180(10 mg/kg)可降低24小时WBC、TNF-α、IL-6、CRP、SCr、BUN(均P<0.05)。
- GSK180干预组SCr为57.67±12.36 μmol/L,低于TIS组的129.67±10.52 μmol/L;BUN为11.63±2.60 mmol/L,低于TIS组的21.53±4.31 mmol/L(均P<0.05)。
- GSK180干预组p-DRP1 Ser616蛋白(p-DRP1 Ser616/DRP1)为0.88±0.15,低于TIS组的1.63±0.13;BAX蛋白(BAX/GAPDH)为1.24±0.13,低于TIS组的2.40±0.26(均P<0.05)。
- GSK180干预组MFN2蛋白(MFN2/GAPDH)为1.09±0.08、OPA1蛋白(OPA1/GAPDH)为1.13±0.07,分别高于TIS组的0.64±0.03和0.74±0.14(均P<0.05)。
- 蛋白质组学显示TIS 24小时组肾组织KMO表达较正常对照组上调,故选择KMO作为后续干预靶点。
适用人群与场景
- 雄性SPF级健康Sprague-Dawley(SD)大鼠,用于建立创伤后脓毒症诱导急性肾损伤模型。
- 正常对照组不接受任何处理;假手术组仅行开腹探查和轻柔盲肠触诊后关腹,术后皮下注射40 mL/kg生理盐水复苏至大鼠恢复自主活动。
处置流程与药物剂量
- KMO抑制剂干预组于造模后2小时腹腔注射GSK180 10 mg/kg;假手术组和TIS组于同一时间点腹腔注射等体积生理盐水。
- 造模后24小时检测炎症指标(WBC、TNF-α、IL-6、CRP)和肾功能指标(SCr、BUN),并取肾组织行PAS染色、TUNEL染色、透射电镜、流式细胞术检测线粒体ROS和膜电位、蛋白质印迹检测KMO、DRP1、p-DRP1 Ser616、MFN2、OPA1、BAX表达。
研究设计与关键结果
- 研究类型为动物实验(大鼠),先建立正常对照组、假手术组及TIS 12、24、48小时组,每组最终保留6只存活大鼠进行统计分析;与正常对照组相比,TIS各组各时间点均出现明显炎症反应和肾功能损伤,于24小时达峰。
- 蛋白质组学分析显示,与正常对照组相比,TIS 24小时组肾组织KMO表达上调,故选择KMO作为后续干预靶点。
- KMO抑制剂干预实验每组保留6只存活大鼠;与TIS组相比,GSK180干预组WBC(×10^9/L)9.87±2.74 vs. 25.10±3.55、TNF-α(ng/L)213.61±81.47 vs. 820.59±105.13、IL-6(ng/L)986.98±105.54 vs. 2376.28±211.80、CRP(ng/L)1149.55±405.60 vs. 3355.76±439.79、SCr(μmol/L)57.67±12.36 vs. 129.67±10.52、BUN(mmol/L)11.63±2.60 vs. 21.53±4.31,均P<0.05。
- 与TIS组相比,GSK180干预组肾脏病理损伤减轻、细胞凋亡减少、线粒体超微结构损伤改善,线粒体ROS水平降低、膜电位稳定,线粒体动力学失衡改善;p-DRP1 Ser616蛋白(p-DRP1 Ser616/DRP1)0.88±0.15 vs. 1.63±0.13、BAX蛋白(BAX/GAPDH)1.24±0.13 vs. 2.40±0.26,均P<0.05;MFN2蛋白(MFN2/GAPDH)1.09±0.08 vs. 0.64±0.03、OPA1蛋白(OPA1/GAPDH)1.13±0.07 vs. 0.74±0.14,均P<0.05。
证据类型、等级与局限
- 证据类型:动物实验(大鼠)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该研究为大鼠实验,作者结论认为KMO在TIS诱导的AKI中上调并介导肾损伤,KMO抑制剂GSK180通过抑制DRP1介导的线粒体分裂、促进MFN2/OPA1依赖的线粒体融合、改善线粒体功能并减轻炎症、氧化应激和细胞凋亡发挥肾脏保护作用。
- 原文未据此给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the protective effect of kynurenine 3-monooxygenase (KMO) inhibitor GSK180 against trauma-induced sepsis (TIS)-induced acute kidney injury (AKI) and to explore its underlying mechanism.
METHODS: Male SPF healthy Sprague-Dawley (SD) rats were randomly divided into groups using a random number table. (1) A normal control group, a sham-operated (Sham) group, and TIS groups at 12, 24, and 48 hours were established, and 6 surviving rats were finally retained in each group for statistical analysis. The normal control group received no treatment. The Sham group was subjected only to laparotomy exploration and gentle cecal palpation followed by abdominal closure, and 40 mL/kg normal saline was injected subcutaneously for fluid resuscitation after surgery until the rats recovered voluntary movement. TIS groups were treated with combined injury to establish the TIS-induced AKI model, and postoperative management was identical to that of the Sham group. Samples were collected at each time point to detect inflammatory indicators such as white blood cell count (WBC), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP), as well as serum creatinine (SCr) and blood urea nitrogen (BUN) to evaluate inflammatory response and renal injury. Based on the severity of renal injury, renal tissues of the corresponding groups were harvested for proteomic analysis to screen candidate target proteins for related mechanistic intervention experiments. (2) In the KMO inhibitor intervention experiment, rats were randomly divided into the Sham group, TIS group, and KMO inhibitor intervention group, with 6 surviving rats retained in each group for statistical analysis. Procedures in the Sham and TIS groups were the same as described above; the KMO inhibitor intervention group was intraperitoneally injected with the KMO inhibitor GSK180 (10 mg/kg) at 2 hours after model establishment, while the Sham and TIS groups were intraperitoneally injected with an equal volume of normal saline. The above inflammatory and renal function indicators were detected at 24 hours after surgery. Periodic acid-Schiff (PAS) staining was used to observe histopathological changes of renal tissues. Terminal-deoxynucleotidyltransferase-mediated dUTP nick-end labeling (TUNEL) staining was adopted to observe cell apoptosis in renal tissues. Mitochondrial ultrastructure changes were examined by transmission electron microscopy. Mitochondrial reactive oxygen species (ROS) and membrane potential were detected by flow cytometry. Western blotting was performed to determine the expression of KMO, mitochondrial dynamics-related proteins [dynamin-related protein 1 (DRP1) and its phosphorylated form at Ser616 (p-DRP1 Ser616), mitofusin 2 (MFN2), optic atrophy protein 1 (OPA1)], and the apoptosis-inducing protein Bcl-2-associated X protein (BAX).
RESULTS: (1) Compared with the normal control group, significant inflammatory response and renal function injury were observed in TIS groups at all-time points, and peaked at the 24 hours, indicating the most severe renal injury at this time point. Proteomic analysis showed that KMO expression was upregulated in renal tissues of the TIS 24-hour group compared with the normal control group, which was thus selected as the target for subsequent intervention. (2) The KMO inhibitor intervention experiment showed that compared with the Sham group, the rats in the TIS group exhibited systemic inflammatory response and renal dysfunction. Pathological observations revealed aggravated renal damage, increased cell apoptosis, and ultrastructural damage. The level of intracellular ROS was elevated, mitochondrial membrane potential was decreased, and mitochondrial dynamics were imbalanced. Compared with the TIS group, KMO inhibition could improve both systemic inflammatory response and renal function, the levels of WBC, TNF-α, IL-6, CRP, SCr, and BUN were decreased [WBC (×109/L): 9.87±2.74 vs. 25.10±3.55, TNF-α (ng/L): 213.61±81.47 vs. 820.59±105.13, IL-6 (ng/L): 986.98±105.54 vs. 2 376.28±211.80, CRP (ng/L): 1 149.55±405.60 vs. 3 355.76±439.79, SCr (μmol/L): 57.67±12.36 vs. 129.67±10.52, BUN (mmol/L): 11.63±2.60 vs. 21.53±4.31, all P<0.05], alleviated histopathological changes in the kidney, ameliorated mitochondrial ultrastructural damage in renal cells, reduced mitochondrial ROS levels and stabilized membrane potential, and both cell apoptosis and mitochondrial dynamics balance had been improved, the phosphorylation level of DRP1 Ser616 and BAX expression were both decreased [p-DRP1 Ser616 protein (p-DRP1 Ser616/DRP1): 0.88±0.15 vs. 1.63±0.13, BAX protein (BAX/GAPDH): 1.24±0.13 vs. 2.40±0.26, both P<0.05], accompanied by upregulated expression of MFN2 and OPA1 [MFN2 protein (MFN2/GAPDH): 1.09±0.08 vs. 0.64±0.03, OPA1 protein (OPA1/GAPDH): 1.13±0.07 vs. 0.74±0.14, both P<0.05].
CONCLUSIONS: KMO is upregulated in TIS-induced AKI and serves as a key factor mediating renal injury. The KMO inhibitor GSK180 exerts renal protective effects by inhibiting DRP1-mediated mitochondrial fission, promoting MFN2/OPA1-dependent mitochondrial fusion, improving mitochondrial function, and alleviating inflammation, oxidative stress and cell apoptosis.
参考来源
- Qian D, Sun B, Dai Z, et al. [Mechanism of kynurenine 3-monooxygenase inhibitor GSK180 in alleviating trauma-induced sepsis-induced acute kidney injury in rats]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2026. PMID: 42200245. doi:10.3760/cma.j.cn121430-20251011-00502
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。